Eurofins Scientific (EUFI) is expanding its high-potency active pharmaceutical ingredient manufacturing operations through its Eurofins CDMO Alphora unit based in Mississauga, Canada.
The expansion targets both standard and high-potency small molecule development programs, reflecting growing industry demand for specialist pharmaceutical manufacturing services.
Eurofins CDMO Alphora has bolstered its kilolab capacity as part of the broader push to serve clients across early and late-stage drug development pipelines.
High-potency APIs require specialist containment facilities and highly controlled manufacturing environments, making capacity expansion in this area a significant operational undertaking.
The Mississauga facility serves as a key node in Eurofins CDMO’s wider global network, which spans multiple sites offering integrated pharmaceutical development services.
Eurofins has worked to align and unify its various CDMO facilities in recent years, creating a more cohesive offering for clients seeking end-to-end drug development support.
The company’s high-potency drug development offering covers API development and production through to formulation and manufacture of both clinical and commercial batches.
This integrated model allows pharmaceutical clients to move a drug candidate through multiple development stages without switching between contract development and manufacturing partners.
Demand for high-potency API manufacturing has grown steadily in recent years, driven in part by the expansion of oncology and other targeted therapy pipelines across the global pharmaceutical sector.
Contract development and manufacturing organisations with established high-potency capabilities are increasingly well-positioned to capture business from both large pharmaceutical companies and emerging biotech firms.
Eurofins Scientific, listed on Euronext Brussels under the ticker EUFI, has built its CDMO division into a significant part of its broader life sciences services portfolio over recent years.
The latest capacity investment underscores the company’s strategy of scaling specialist manufacturing capabilities to meet client demand across complex small molecule drug programs.